key: cord-1046164-aptu4xd9 authors: Kang, Chang Kyung; Choe, Pyoeng Gyun; Park, Sungman; Kim, Taek Soo; Seong, Moon‐Woo; Kim, Nam‐Joong; Oh, Myoung‐don; Park, Wan Beom; Kim, Yoon‐Won title: Compassionate use of hzVSF‐v13 in two patients with severe COVID‐19 date: 2020-06-03 journal: J Med Virol DOI: 10.1002/jmv.26063 sha: c20ea7cf808f5cba570806550e278a23208187a8 doc_id: 1046164 cord_uid: aptu4xd9 We report the compassionate use of humanized Virus Suppressing Factor-variant 13 (hzVSF-v13) in two patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Both patients, including an 81-year-old man who required extracorporeal membrane oxygenation, showed clinical improvement. These results warrant placebo-controlled trials to evaluate the hzVSF-v13 efficacy against COVID-19. This article is protected by copyright. All rights reserved. 1 (MCP-1), interferon-γ, and IL-2 following the manufacturer's instructions. Nasopharyngeal swab samples were collected three times a week and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral loads were quantified as previously described. 5 There were two patients who met the above criteria, and both agreed receiving compassionate hzVSF-v13. They were 81-and 29-year-old men, with critical and severe COVID-19 pneumonia, 6 respectively (Supporting Information Table) . The first patient had no preexisting medical condition. Upon admission (12th day of illness), he had been receiving lopinavir and ritonavir. However, his condition had worsened, and he underwent mechanical ventilation and extracorporeal membrane oxygenation (21st and 23rd day of illness, respectively). Bacterial and fungal cultures were negative. We administered Neither patient experienced hzVSF-v13-elicited adverse events. In this study, two patients with COVID-19 pneumonia, who received compassionate hzVSF-v13 therapy, recovered successfully. Inflammatory markers or viral loads declined after the administration of hzVSF-v13, followed by an improvement in oxygenation profile. Notably, the 81-year-old man who required extracorporeal membrane oxygenation and continuous renal replacement treatment because of severe pneumonia and multiorgan failure also recovered. As viral load and worsening of symptoms are not well-correlated in COVID-19, 7, 8 anti-inflammatory effect as well as antiviral activity might be crucial in treating COVID-19. 8 We showed that hzVSF-v13 treatment not only reduced the viral load but also decreased proinflammatory cytokine levels. Therefore, hzVSF-v13 may be a promising drug for treating COVID-19. We should interpret the results cautiously because of the small sample size and the single-arm nature of our study. In addition, as hzVSF-v13 was not administered in the early course of COVID-19 in the present study, examining its sole therapeutic effect is difficult. We do not know if the patients' conditions or cytokine levels would have improved without hzVSF-v13 treatment. Nonetheless, considering the lack of approved therapeutics, the efficacy of hzVSF-v13 against COVID-19 is worth further evaluation. We report two patients with COVID-19 pneumonia who recovered after the compassionate use of hzVSF-v13. Our findings warrant placebo-controlled clinical trials to evaluate the efficacy of F I G U R E 1 Clinical courses, quantification of SARS-CoV-2 viral loads, and inflammatory markers in two patients (panel A and B, respectively) treated with hzVSF-v13 in this study. CRP, C-reactive protein; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; IFN-γ, interferon-γ; MCP-1, monocyte chemoattractant protein-1; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF-α, tumor necrosis factor-α Guidelines on the treatment and management of patients with COVID-19 infection Im-muneMed Inc., assignee. An antibody or peptide specifically binding to peptide derived from vimentin pharmacokinetic characteristics of hzVSF-v13 in healthy male volunteers Treatment of 5 critically ill patients with COVID-19 with convalescent plasma Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2 Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the chinese center for disease control and prevention Clinical features of patients infected with 2019 novel coronavirus in Wuhan COVID-19: combining antiviral and anti-inflammatory treatments